Brooks Running’s year-to-date global revenues are up 5 percent and 7 percent higher year-over-year in the US as the Seattle-based company has reached new runners, recovered from Covid-19-related supply chain disruptions, and normalized inventory levels. Year-to-date sales for the brand in France and the UK combined are up 22 percent, the company said, and there were unspecified market gains in China during Q3 ended Sept. 30. Crediting the strong September launch of its Ghost Max style, Brooks is confident it will achieve double-digit sales growth in 2024. New and expanded distribution centers in the UK and the US have tripled the company’s distribution facility footprint, which will enable the scaling of operations to meet increased demand across channels.
In January, Brooks will introduce the Glycerin 21, the next generation of a fan favorite, featuring additional DNA Loft v3 cushioning, and debut the Hyperion Elite 4 distance racing shoe ahead of the 2024 US Olympic Marathon Team Trials in February. Also, in early 2024, the brand will make its new 3D-printed midsole technology, 3DNA, available in limited quantities in the Exhilarate-BL to members of its loyalty program.
According to Upper Quadrant Specialty Run market data, Brooks currently has five of the top 10 selling running shoes in the US specialty run retail channel. The brand also owned a 21.4 percent market share in the US retail adult performance running shoe market, achieving the top spot in the segment for a seventh consecutive period in Q3, according to Circana’s retail tracking service.
